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Reply
We thank Dr. Kennedy and colleagues and Dr. Koh for their
interest in our paper (1). In response to Dr. Kennedy, we
previously compared the strengths of the 4 major risk factors for
diabetes across 3 large statin trials (2). Fasting blood sugar is the
strongest predictor, which is not a surprise because it is used for the
diagnosis of diabetes. Age was considered, but was not a predictor
of diabetes in any of these 3 trials (2).
We agree with Dr. Kennedy that the incidence of diabetes may
e underestimated in these trials. Unfortunately, the risk of
iabetes with statins was not recognized when these trials were
esigned and executed. Thus, endpoint ascertainment is highly
eliable for cardiovascular events, but less so for diabetes. Meta-
nalyses clearly show a stepwise increase in incident diabetes from
lacebo to low-dose to high-dose statin therapy, with the incre-
ents being 9% and 16%, respectively (3,4).
Data from clinical trials indicate that the deterioration in
lycemic control related to statins in patients with diabetes may
ot be as large as that suggested by Dr. Kennedy and colleagues. In
ARDS (Collaborative Atorvastatin Diabetes Study), where
,838 patients with type 2 diabetes were randomized to atorvasta-
in 10 mg/day or placebo and followed for a median of 3.9 years
5), the adjusted mean difference in HbA1C between the treatment
roups at the end of the study was only 0.105% (p  0.03). In the
SPEN (Atorvastatin Study for Prevention of Coronary Heart
isease Endpoints in Non-insulin-dependent Diabetes) study,
here 2,410 patients with type 2 diabetes were randomized to
torvastatin 10 mg/day or placebo and followed for 4 years, the
hanges in HbA1C were identical, 0.2%, in the 2 treatment groups
6). A random sample of 1,087 participants with diabetes in the
eart Protection Study had HbA1C measurements at baseline and
after an average of 4.6 years of follow-up. The increase in HbA1C
was slightly but not statistically significantly higher in the simva-
statin 40 mg group compared to placebo (7).
Neither the TNT (Treating to New Targets) study nor the
DEAL (Incremental Decrease in End points through Aggressive
ipid lowering) study was powered to show a significant decrease
n overall or cardiovascular mortality. Indeed, in the meta-analysis
f more versus less intensive statin therapy (which included the
NT and IDEAL studies), the overall incidence of coronary heart
isease (CHD) death was only 0.7% (8). Nevertheless, the com-
ined endpoint of CHD death or nonfatal MI was reduced
relative risk: 0.71; 95% confidence interval: 0.58 to 0.87 per 1
mol/l reduction in low-density lipoprotein cholesterol), as were
ther important endpoints such as ischemic stroke and coronary
evascularization. The benefits of more intensive statin therapy
re clearly established.
We disagree with Dr. Koh’s conclusion that “higher dose statin
herapy does not have any benefit compared with lower dose statin
herapy,” both for the reason described in the preceding paragraph,
nd because the impact of new onset diabetes is relatively minor
ompared to the cardiovascular events included in our analysis:
HD death, myocardial infarction, resuscitated cardiac arrest, and
atal or nonfatal stroke. Comparing one hazard ratio to another ismisleading because the types of events are not equivalent. As noted
in our paper, nearly 20% of patients with an event had more than
one of them, and other cardiovascular events that are prevented by
statin treatment such as coronary revascularization, new onset
angina, and transient ischemic attack were not included in our
analysis.
Dr. Koh speculates that the long-term adverse effects of new
onset diabetes with statins might generate a relative increase in
deaths, and cites data from the JUPITER (Justification for the Use
of statins in Prevention: an Intervention Trial Using Rosuvastatin)
trial as support. The median follow-up of JUPITER trial patients
was only 1.9 years, and despite a significant increase in incident
diabetes in the rosuvastatin treatment group, all major cardiovas-
cular events were reduced by nearly half. Even among the patients
who did develop diabetes during the trial, rosuvastatin was asso-
ciated with a risk reduction similar to that seen in the overall group
(9). We agree with the conclusion of that report, that “the
cardiovascular and mortality benefits of statin therapy exceed the
diabetes hazard, including in participants at high risk of developing
diabetes.”
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